Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheeba K Thomas

Showing results (51-60 of 114) with videos related to

Pageof 12
Sort By:
Bone Marrow Transplantation|November 18, 2018
Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugsLohith Gowda, Mithun Shah, Ifra Badar, et al.
American Journal of Hematology|February 19, 2026
A Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in AL AmyloidosisHans C Lee, Melody R Becnel, Lei Feng, et al.
Leukemia & Lymphoma|July 5, 2017
A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single centerGhulam Rehman Mohyuddin, Muhammad Salman Faisal, Talha Badar, et al.
British Journal of Haematology|February 26, 2013
A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myelomaPeter M Voorhees, Robert F Manges, Pieter Sonneveld, et al.
Annals of Hematology|March 25, 2017
Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myelomaMuhamed Baljevic, Shadia Zaman, Veerabhadran Baladandayuthapani, et al.
Nature Communications|August 11, 2024
Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trialSzymon J Szymura, Lin Wang, Tiantian Zhang, et al.
British Journal of Haematology|January 24, 2021
Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapiesElisabet E Manasanch, David Berrios, Eric Fountain, et al.
American Journal of Hematology|December 15, 2018
Long-term durable efficacy of autologous stem cell transplantation in POEMS syndromeNeeraj Y Saini, Romil D Patel, Ankur Varma, et al.
Blood Advances|April 15, 2026
Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-upRoger G Owen, Helen McCarthy, Shirley D'Sa, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 26, 2015
Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell TransplantationRyan W Jacobs, Rima M Saliba, Koji Sasaki, et al.
Pageof 12

Showing results (51-60 of 114) with videos related to

Sort By:
Pageof 12
Bone Marrow Transplantation|November 18, 2018
Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugsLohith Gowda, Mithun Shah, Ifra Badar, et al.
American Journal of Hematology|February 19, 2026
A Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in AL AmyloidosisHans C Lee, Melody R Becnel, Lei Feng, et al.
Leukemia & Lymphoma|July 5, 2017
A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single centerGhulam Rehman Mohyuddin, Muhammad Salman Faisal, Talha Badar, et al.
British Journal of Haematology|February 26, 2013
A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myelomaPeter M Voorhees, Robert F Manges, Pieter Sonneveld, et al.
Annals of Hematology|March 25, 2017
Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myelomaMuhamed Baljevic, Shadia Zaman, Veerabhadran Baladandayuthapani, et al.
Nature Communications|August 11, 2024
Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trialSzymon J Szymura, Lin Wang, Tiantian Zhang, et al.
British Journal of Haematology|January 24, 2021
Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapiesElisabet E Manasanch, David Berrios, Eric Fountain, et al.
American Journal of Hematology|December 15, 2018
Long-term durable efficacy of autologous stem cell transplantation in POEMS syndromeNeeraj Y Saini, Romil D Patel, Ankur Varma, et al.
Blood Advances|April 15, 2026
Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-upRoger G Owen, Helen McCarthy, Shirley D'Sa, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 26, 2015
Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell TransplantationRyan W Jacobs, Rima M Saliba, Koji Sasaki, et al.
Pageof 12